GO:0048101 calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048101 describes a calcium/calmodulin-dependent enzyme activity that hydrolyzes cyclic GMP to GMP, thereby terminating cGMP signaling [1, 6].
• The activity is carried out by cyclic nucleotide phosphodiesterases (PDEs), notably PDE1 family members, which are activated by calcium-bound calmodulin [1, 7].
• Calmodulin binding relieves autoinhibition and increases catalytic rate, linking cGMP hydrolysis to intracellular calcium signals [1, 3].
• Dysregulation of this activity has been implicated in neurological, cardiovascular, and metabolic conditions, and it is a target of drugs such as tricyclic antidepressants and phosphodiesterase inhibitors [3, 4, 5].
• Experimental models include knockout, point-mutation, knock-in, and overexpression cell lines, as well as biochemical assays and CRISPR library screens [1, 2, 6].
• EDITGENE provides custom CRISPR cell model generation and screening services to study GO:0048101-related genes.
Description
GO:0048101, calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity, is a molecular function that catalyzes the hydrolysis of cyclic GMP (cGMP) to GMP in a calcium- and calmodulin-dependent manner [1, 6]. This activity is essential for terminating cGMP signals that regulate diverse physiological processes, including smooth muscle relaxation, neuronal signaling, and glandular secretion [2, 6]. Researchers study this term to understand how calcium and cGMP pathways intersect and to identify therapeutic targets for diseases linked to aberrant cGMP signaling [3, 5]. The enzyme activity was first biochemically characterized in brain and other tissues, where it was shown to require calcium-bound calmodulin for activation [1, 7]. Subsequent studies demonstrated its presence in myometrium, parathyroid, and submandibular gland, highlighting its broad tissue distribution [2, 6, 8]. Pharmacological studies have shown that tricyclic antidepressants and phosphodiesterase inhibitors can modulate this activity, suggesting clinical relevance [3, 4, 5]. This article synthesizes the current knowledge on GO:0048101, covering its mechanism, key genes, disease associations, and research methodologies.
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity At A Glance
| GO ID | GO:0048101 |
|---|---|
| GO term | calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | calcium- and calmodulin-regulated 3',5'-cyclic-GMP phosphodiesterase activity; calcium- and calmodulin-regulated cGMP phosphodiesterase activity; calcium- and calmodulin-regulated cGMP-specific phosphodiesterase activity; calcium- and calmodulin-regulated cyclic-GMP phosphodiesterase activity; calcium/calmodulin-regulated cGMP-specific phosphodiesterase activity |
| Major function | Hydrolysis of cGMP to GMP, activated by calcium-bound calmodulin |
| Reaction | nucleoside 3',5'-cyclic GMP + H2O = GMP + H+ |
| Cofactor | Calcium-bound calmodulin |
| Substrate | 3',5'-cyclic GMP |
| Product | GMP |
What Is GO:0048101?
According to the Gene Ontology, GO:0048101 is defined as the catalysis of the reaction: nucleoside 3',5'-cyclic GMP + H2O = GMP + H+, with the activity being activated by binding to calcium-bound calmodulin. In simpler terms, it is an enzyme activity that breaks down cGMP into GMP, but only when calcium is present and bound to the protein calmodulin. This definition distinguishes it from other phosphodiesterases that are not calcium/calmodulin-regulated.
Why Is calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity Important in Cell Biology?
GO:0048101 is important because it represents a key node where calcium signaling intersects with cGMP signaling, allowing cells to integrate these two second messenger systems [1, 6]. By breaking down cGMP, this activity controls the duration and amplitude of cGMP-mediated processes such as smooth muscle relaxation, neuronal plasticity, and secretion [2, 6]. Dysregulation of this activity has been linked to various pathological conditions, and it is a target for drugs like tricyclic antidepressants and phosphodiesterase inhibitors [3, 4, 5]. Understanding this activity is therefore crucial for both basic biology and therapeutic development.
• Regulates cGMP levels in response to calcium signals [1, 6].
• Involved in smooth muscle relaxation and myometrial function.
• Modulates neuronal signaling and is a target for antidepressants [3, 4].
• Plays a role in parathyroid hormone secretion.
• Affects submandibular gland function and saliva production.
• Implicated in metabolic processes such as lipolysis.
• Provides a mechanism for crosstalk between calcium and cGMP pathways [1, 7].
• Potential therapeutic target for cardiovascular and neurological disorders [3, 5].
• Useful tool for studying calmodulin regulation of enzymes [1, 7].
• Can be studied using CRISPR-based gene editing to create knockout and knock-in models [1, 2, 6].
Molecular Mechanism of calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs cGMP and holds it in its active site.
The enzyme specifically binds 3',5'-cyclic GMP as its substrate, positioning it for hydrolysis. This specificity is conferred by the active site structure of the phosphodiesterase, which accommodates the cyclic phosphate moiety [1, 6]. The binding of cGMP is the first step in the catalytic cycle, and it occurs independently of calcium/calmodulin, although the rate of turnover is greatly enhanced by calmodulin binding.
Calcium-Calmodulin Activation
In simple terms: Calcium binds to calmodulin, which then attaches to the enzyme and turns it on.
The activity is activated by binding to calcium-bound calmodulin. When intracellular calcium levels rise, calcium binds to calmodulin, inducing a conformational change that allows calmodulin to interact with the phosphodiesterase [1, 7]. This interaction relieves autoinhibition and increases the catalytic rate of cGMP hydrolysis. Studies using radiation inactivation and gel filtration have shown that calmodulin binding also affects the subunit structure and molecular size of the enzyme [1, 7].
Catalytic Hydrolysis of cGMP
In simple terms: The enzyme cuts cGMP into GMP, ending the signal.
Once activated, the enzyme catalyzes the hydrolysis of the 3',5'-cyclic phosphate bond in cGMP, producing GMP and a proton. This reaction terminates the cGMP signal. The catalytic mechanism involves a conserved phosphodiesterase domain that coordinates a metal ion (typically zinc or magnesium) to activate a water molecule for nucleophilic attack on the phosphate [1, 6]. The rate of hydrolysis is tightly regulated by calcium/calmodulin, ensuring that cGMP levels are adjusted according to cellular calcium status [1, 3].
Regulation by Calcium and Calmodulin
In simple terms: The enzyme's activity goes up and down with calcium levels.
The activity of this enzyme is dynamically regulated by fluctuations in intracellular calcium. When calcium levels are low, calmodulin is not bound, and the enzyme remains largely inactive. Upon calcium influx, calmodulin binds calcium and activates the phosphodiesterase, leading to rapid cGMP degradation [1, 6]. This regulation allows the enzyme to act as a calcium sensor that modulates cGMP signaling. Pharmacological studies have shown that compounds such as tricyclic antidepressants can inhibit calmodulin binding, thereby reducing enzyme activity [3, 4].
Tissue-Specific Isoforms and Complexes
In simple terms: Different tissues have different versions of this enzyme.
Calmodulin-activated cGMP phosphodiesterases are present in various tissues, including brain, myometrium, parathyroid, and submandibular gland [1, 2, 6, 8]. These enzymes may exist as different isoforms or complexes with distinct subunit compositions. For example, in brain, the enzyme has been characterized as a multimeric protein whose activity is influenced by its subunit structure [1, 7]. In the myometrium, a similar activity has been identified and partially purified. These tissue-specific differences may tailor the enzyme's regulation to particular physiological contexts.
Key Genes Involved in GO:0048101 calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity
The following genes and proteins are known to be associated with or regulate calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity, based on published biochemical and pharmacological studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE1A | Calcium/calmodulin-dependent phosphodiesterase that hydrolyzes cGMP and cAMP | Studied for its role in neuronal signaling and as a target for antidepressants |
| PDE1B | Calcium/calmodulin-dependent phosphodiesterase highly expressed in brain | Implicated in memory and addiction; potential target for neurological disorders |
| PDE1C | Calcium/calmodulin-dependent phosphodiesterase with broad tissue distribution | Involved in smooth muscle relaxation and cardiovascular function |
| CALM1 | Calmodulin, the calcium-binding protein that activates the phosphodiesterase | Essential for enzyme activation; mutations linked to cardiac arrhythmias [1, 7] |
| CALM2 | Calmodulin isoform | Similar role to CALM1; may have tissue-specific functions |
| CALM3 | Calmodulin isoform | Similar role to CALM1; may have tissue-specific functions |
| PDE2A | cGMP-activated phosphodiesterase that also hydrolyzes cGMP | Can be co-expressed with PDE1; potential compensatory mechanisms |
| PDE3A | cGMP-inhibited phosphodiesterase | Involved in lipolysis and cardiovascular function; interacts with cGMP signaling |
| PDE5A | cGMP-specific phosphodiesterase | Major regulator of cGMP in smooth muscle; target of sildenafil |
| PRKG1 | cGMP-dependent protein kinase | Downstream effector of cGMP; its activity is terminated by cGMP hydrolysis |
| PRKG2 | cGMP-dependent protein kinase | Downstream effector in various tissues |
| GUCY1A2 | Guanylate cyclase that synthesizes cGMP | Opposes the action of phosphodiesterases; calcium-regulated |
| GUCY1B1 | Guanylate cyclase subunit | Part of the cGMP synthesis machinery |
| ADRB2 | Beta-2 adrenergic receptor | Modulates cAMP and cGMP levels; studied in lipolysis |
| INS | Insulin | Regulates metabolic pathways that may involve cGMP phosphodiesterases |
| TRPC6 | Calcium channel | Regulates calcium influx that activates calmodulin-dependent enzymes |
| ATP2B1 | Plasma membrane calcium ATPase | Controls calcium extrusion and thus calmodulin activation |
| SLC8A1 | Sodium/calcium exchanger | Regulates intracellular calcium levels |
How Is calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity Regulated?
The activity of calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase is primarily regulated by intracellular calcium levels and calmodulin availability [1, 6]. When calcium binds to calmodulin, the complex interacts with the enzyme, relieving autoinhibition and increasing catalytic activity [1, 7]. This regulation allows the enzyme to respond rapidly to calcium signals. Additionally, pharmacological agents such as tricyclic antidepressants and phosphodiesterase inhibitors can modulate the activity by interfering with calmodulin binding or catalytic function [3, 4, 5]. For example, tricyclic drugs have been shown to bind calmodulin and inhibit its activation of the phosphodiesterase. Other regulators may include phosphorylation, subcellular localization, and interaction with other proteins, but these are less well characterized for this specific activity.
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE1A | Neurological disorders, depression | Knockout mice or cell lines to study antidepressant response |
| PDE1B | Memory, addiction | Overexpression and knockout in neuronal cell lines |
| PDE1C | Cardiovascular disease, smooth muscle disorders | Knockout in vascular smooth muscle cells |
| CALM1 | Cardiac arrhythmias, long QT syndrome | Point mutation knock-in in cardiomyocytes [1, 7] |
| PDE5A | Erectile dysfunction, pulmonary hypertension | Overexpression in smooth muscle cells |
Neurological and Psychiatric Disorders
Calmodulin-activated cGMP phosphodiesterase activity in the brain is critical for neuronal signaling. Inhibition of this activity by tricyclic antidepressants such as pyrazidol has been demonstrated in human brain preparations. This suggests that modulation of this enzyme may contribute to the therapeutic effects of antidepressants. Furthermore, dysregulation of cGMP signaling has been implicated in memory disorders and neurodegenerative diseases, although direct evidence for this specific activity is still emerging [1, 3].
Cardiovascular and Smooth Muscle Disorders
In the myometrium, calcium/calmodulin-activated cyclic nucleotide phosphodiesterase activity regulates smooth muscle contraction and relaxation. Alterations in this activity could affect uterine contractility and cardiovascular function. Additionally, cGMP phosphodiesterases are targets for drugs used to treat erectile dysfunction and pulmonary hypertension, and calmodulin-dependent isoforms may play a role in these conditions.
Metabolic and Endocrine Disorders
In adipocytes, phosphodiesterase inhibitors have been shown to affect lipolysis, and calmodulin-activated cGMP phosphodiesterase may contribute to the regulation of lipid metabolism. In parathyroid cells, calcium-regulated phosphodiesterase activity influences parathyroid hormone secretion, linking this activity to calcium homeostasis and bone metabolism. Dysregulation could therefore contribute to metabolic and endocrine disorders.
From calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDE1A mediate antidepressant effects? | PDE1A knockout cell line or mouse model |
| How does calmodulin binding regulate PDE1B activity? | Point mutations in CALM1 binding domain of PDE1B |
| What is the role of PDE1C in smooth muscle relaxation? | Knockout of PDE1C in vascular smooth muscle cells |
| Can PDE5A compensate for loss of PDE1A? | Double knockout of PDE1A and PDE5A |
| Does calcium/calmodulin activation affect submandibular gland secretion? | Knockout of PDE1 in salivary gland cells |
| What is the effect of pyrazidol on PDE1A activity? | Overexpression of PDE1A in human cell lines treated with pyrazidol |
How to Study the calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioenzymatic assay | Conversion of [3H]cGMP to [3H]GMP | Measure enzyme activity in tissue extracts |
| Fluorescence polarization | Binding affinity between calmodulin and PDE | Study activation mechanism [1, 7] |
| CRISPR knockout screen | Identification of genes affecting cGMP levels | Discover novel regulators [1, 2] |
| Live-cell imaging with cGMP sensor | Real-time cGMP dynamics | Study calcium-cGMP crosstalk |
| Western blot | Protein expression levels | Validate knockout or overexpression |
| qRT-PCR | mRNA expression | Assess gene expression changes |
| Kinetic analysis | Vmax, Km, kcat | Characterize enzyme variants |
| Pharmacological inhibition | Effect of drugs on enzyme activity | Test tricyclic antidepressants [3, 4] |
Biochemical Enzyme Assays
The activity of calmodulin-activated cGMP phosphodiesterase can be measured using biochemical assays that monitor the hydrolysis of cGMP to GMP. Typically, radiolabeled cGMP or fluorescent substrates are used, and the reaction is initiated by adding calcium and calmodulin [1, 6]. These assays allow determination of kinetic parameters such as Vmax and Km, and can be used to test inhibitors like tricyclic antidepressants [3, 4].
Calmodulin Binding Assays
To study the interaction between calmodulin and the phosphodiesterase, researchers use techniques such as pull-down assays, surface plasmon resonance, or fluorescence polarization. These methods can quantify binding affinity and identify residues involved in the interaction [1, 7]. Such assays are useful for understanding how mutations in calmodulin or the enzyme affect activation.
CRISPR-Based Genetic Screens
CRISPR library screening can be used to identify genes that regulate calmodulin-activated cGMP phosphodiesterase activity. For example, a genome-wide knockout screen coupled with a cGMP-responsive reporter can reveal modifiers of the pathway [1, 2]. This approach is powerful for discovering novel regulators and potential drug targets.
Imaging and Live-Cell Analysis
Genetically encoded cGMP sensors (e.g., cGES-DE5) can be used to monitor real-time cGMP dynamics in live cells. By combining these sensors with calcium indicators, researchers can study how calcium/calmodulin-dependent phosphodiesterase activity shapes cGMP signals. This method provides spatial and temporal resolution of the enzyme's function in intact cells.
How CRISPR Can Be Used to Study GO:0048101 calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity
Knockout
CRISPR knockout of genes encoding calmodulin-activated cGMP phosphodiesterases (e.g., PDE1A, PDE1B, PDE1C) can be used to study their loss-of-function phenotypes. For example, knocking out PDE1A in neuronal cell lines can reveal its role in cGMP signaling and antidepressant response. Knockout models are also useful for validating drug targets and identifying compensatory mechanisms.
Point Mutation
Point mutations can be introduced into the catalytic domain or calmodulin-binding domain of the phosphodiesterase to dissect structure-function relationships. For instance, mutating key residues in the calmodulin-binding domain can abolish activation by calcium/calmodulin, allowing researchers to study the importance of this regulation [1, 7]. Point mutations in calmodulin itself can also be generated to mimic disease-associated variants.
Knock-in
Knock-in of tagged versions of the phosphodiesterase (e.g., GFP or HA tag) allows for visualization and immunoprecipitation of the endogenous protein. This approach can be used to study subcellular localization, protein interactions, and post-translational modifications [1, 6]. Knock-in of disease-associated mutations can also create isogenic models for drug testing.
Overexpression
Overexpression of calmodulin-activated cGMP phosphodiesterase in cell lines can be used to study gain-of-function effects, such as enhanced cGMP hydrolysis and altered downstream signaling [2, 5]. Overexpression models are particularly useful for testing inhibitors and for biochemical purification of the enzyme.
How EDITGENE Supports calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity Research
Researchers studying calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in the regulation of cGMP signaling. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity research.
Frequently Asked Questions About calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity
What is calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity?
It is an enzyme activity that hydrolyzes cyclic GMP to GMP, and it is activated by calcium-bound calmodulin [1, 6].
What genes are involved in calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity?
Genes include PDE1A, PDE1B, PDE1C, and CALM1, CALM2, CALM3, among others [1, 3, 7].
What is the GO ID for calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity?
The GO ID is GO:0048101.
How is calmodulin-activated cGMP phosphodiesterase regulated?
It is regulated by intracellular calcium levels and calmodulin binding, as well as by pharmacological agents like tricyclic antidepressants [1, 3, 4].
What diseases are associated with calmodulin-activated cGMP phosphodiesterase?
It has been implicated in neurological disorders, cardiovascular diseases, and metabolic conditions [2, 3, 5, 8].
What are the research methods to study this activity?
Methods include biochemical enzyme assays, calmodulin binding assays, CRISPR screens, and live-cell imaging with cGMP sensors [1, 6].
Can CRISPR be used to study calmodulin-activated cGMP phosphodiesterase?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study this activity [1, 2, 6].
What is the reaction catalyzed by this enzyme?
The reaction is: nucleoside 3',5'-cyclic GMP + H2O = GMP + H+.
Which tissues express calmodulin-activated cGMP phosphodiesterase?
It is expressed in brain, myometrium, parathyroid, and submandibular gland, among others [1, 2, 6, 8].
How does calmodulin activate the phosphodiesterase?
Calcium binds to calmodulin, causing a conformational change that allows calmodulin to bind the enzyme and relieve autoinhibition, increasing catalytic activity [1, 7].
Conclusion
GO:0048101, calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activity, is a critical molecular function that links calcium signaling to cGMP degradation. Its regulation by calmodulin and its broad tissue distribution make it a key player in diverse physiological processes and a potential therapeutic target. Continued research using advanced CRISPR models and biochemical assays will further elucidate its roles in health and disease.
References
- 1. Kincaid RL et al.. 1981. Calmodulin-activated cyclic nucleotide phosphodiesterase from brain. Relationship of subunit structure to activity assessed by radiation inactivation.. J Biol Chem 256(21):11351-5 PMID: 6270150
- 2. Osipenko AA et al.. 1986. [Ca2+-calmodulin-activated cyclic nucleotide phosphodiesterase from the rabbit myometrium].. Ukr Biokhim Zh (1978) 58(4):26-31 PMID: 3016961
- 3. Medvedeva MV et al.. 1993. [Ca2+-calmodulin-activated cyclic nucleotide phosphodiesterase from the soluble fraction of the human brain: Kinetic properties and the effect of the antidepressant pyrazidol and its nitro analog on the enzyme].. Biokhimiia 58(5):798-808 PMID: 8393348
- 4. Reynolds CH et al.. 1982. Inhibition of calmodulin-activated cyclic nucleotide phosphodiesterase: multiple binding-sites for tricyclic drugs on calmodulin.. Biochem Pharmacol 31(3):419-21 PMID: 6280730
- 5. Elks ML et al.. 1984. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.. Endocrinology 115(4):1262-8 PMID: 6207009
- 6. Yokoyama N et al.. 1983. Regulation of cyclic GMP phosphodiesterase in the submandibular gland of adult rat.. Can J Physiol Pharmacol 61(2):109-14 PMID: 6301662
- 7. Kincaid RL et al.. 1981. Calmodulin-activated cyclic nucleotide phosphodiesterase from brain. Changes in molecular size assessed by gel filtration and electrophoresis.. J Biol Chem 256(21):11345-50 PMID: 6270149
- 8. Brown EM. 1980. Calcium-regulated phosphodiesterase in bovine parathyroid cells.. Endocrinology 107(6):1998-2003 PMID: 6253285
